Top

Published in:

28-06-2023 | Hepatocellular Carcinoma | Review

N6-methyladenosine RNA methylation in liver diseases: from mechanism to treatment

Authors: Lan Yang, Siyuan Tian, Xiaohong Zheng, Miao Zhang, Xinmin Zhou, Yulong Shang, Ying Han

Published in: Journal of Gastroenterology | Issue 8/2023

Abstract

Epigenetic modification occurring in RNA has become the hotspot of the field. N6-methyladenosine (m6A) methylation is the most abundant RNA internal modification mainly occurring at the consensus motif DR (m6A) CH (D = A/G/U, R = A/G, H = A/C/U) in the 3’-UTR particularly the region near stop codons. The life cycle of m6A methylation includes “writers,” “erasers,” and “readers”, which are responsible for the addition, removal, and recognition of m6A, respectively. m6A modification has been reported changing RNA secondary structure or modulating the stability, localization, transport, and translation of mRNAs to play crucial roles in various physiological and pathological conditions. Liver, as the largest metabolic and digestive organ, modulates vital physiological functions, and its dysfunction gives rise to the occurrence of various diseases. Despite the advanced intervening measures, mortality due to liver diseases is continuously high. Recent studies have explored the roles of m6A RNA methylation in the pathogenesis of liver diseases, providing new insights for studying the molecular mechanism of liver diseases. In the review, we extensively summarize the life cycle of m6A methylation, as well as its function and relevant mechanisms in liver fibrosis (LF), nonalcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), hepatitis virus infection, and hepatocellular carcinoma (HCC), and eventually we explore the potential of m6A as a treatment option for these liver diseases.

Dominissini D, Moshitch-Moshkovitz S, Schwartz S, et al. Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature. 2012;485:201–6.PubMed

Saneyoshi M, Harada F, Nishimura S. Isolation and characterization of N6-methyladenosine from Escherichia coli valine transfer RNA. Biochim Biophys Acta. 1969;190:264–73.PubMed

Iwanami Y, Brown GM. Methylated bases of ribosomal ribonucleic acid from HeLa cells. Arch Biochem Biophys. 1968;126:8–15.PubMed

Yang Y, Fan X, Mao M, et al. Extensive translation of circular RNAs driven by N(6)-methyladenosine. Cell Res. 2017;27:626–41.PubMedPubMedCentral

Meyer KD, Saletore Y, Zumbo P, et al. Comprehensive analysis of mRNA methylation reveals enrichment in 3’ UTRs and near stop codons. Cell. 2012;149:1635–46.PubMedPubMedCentral

Bokar JA, Shambaugh ME, Polayes D, et al. Purification and cDNA cloning of the AdoMet-binding subunit of the human mRNA (N6-adenosine)-methyltransferase. RNA. 1997;3:1233–47.PubMedPubMedCentral

Liu J, Yue Y, Han D, et al. A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat Chem Biol. 2014;10:93–5.PubMed

Wang P, Doxtader KA, Nam Y. Structural basis for cooperative function of Mettl3 and Mettl14 methyltransferases. Mol Cell. 2016;63:306–17.PubMedPubMedCentral

Ping XL, Sun BF, Wang L, et al. Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase. Cell Res. 2014;24:177–89.PubMedPubMedCentral

10.

Warda AS, Kretschmer J, Hackert P, et al. Human METTL16 is a N(6)-methyladenosine (m(6)A) methyltransferase that targets pre-mRNAs and various non-coding RNAs. EMBO Rep. 2017;18:2004–14.PubMedPubMedCentral

11.

Ma H, Wang X, Cai J, et al. N(6-)methyladenosine methyltransferase ZCCHC4 mediates ribosomal RNA methylation. Nat Chem Biol. 2019;15:88–94.PubMed

12.

van Tran N, Ernst FGM, Hawley BR, et al. The human 18S rRNA m6A methyltransferase METTL5 is stabilized by TRMT112. Nucl Acids Res. 2019;47:7719–33.PubMedPubMedCentral

13.

Peng H, Chen B, Wei W, et al. N(6)-methyladenosine (m(6)A) in 18S rRNA promotes fatty acid metabolism and oncogenic transformation. Nat Metab. 2022;4:1041–54.PubMed

14.

Jia G, Fu Y, Zhao X, et al. N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat Chem Biol. 2011;7:885–7.PubMedPubMedCentral

15.

Linder B, Grozhik AV, Olarerin-George AO, et al. Single-nucleotide-resolution mapping of m6A and m6Am throughout the transcriptome. Nat Methods. 2015;12:767–72.PubMedPubMedCentral

16.

Wei J, Liu F, Lu Z, et al. Differential m(6)A, m(6)Am, and m(1)A demethylation mediated by FTO in the cell nucleus and cytoplasm. Mol Cell. 2018;71(973–85): e5.

17.

Fu Y, Jia G, Pang X, et al. FTO-mediated formation of N6-hydroxymethyladenosine and N6-formyladenosine in mammalian RNA. Nat Commun. 2013;4:1798.PubMed

18.

Wang T, Kong S, Tao M, et al. The potential role of RNA N6-methyladenosine in Cancer progression. Mol Cancer. 2020;19:88.PubMedPubMedCentral

19.

Huang H, Weng H, Chen J. m(6)A modification in coding and non-coding RNAs: roles and therapeutic implications in cancer. Cancer Cell. 2020;37:270–88.PubMedPubMedCentral

20.

Shi H, Wei J, He C. Where, when, and how: context-dependent functions of RNA methylation writers, readers, and erasers. Mol Cell. 2019;74:640–50.PubMedPubMedCentral

21.

Liu T, Wei Q, Jin J, et al. The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation. Nucl Acids Res. 2020;48:3816–31.PubMedPubMedCentral

22.

Zhuang M, Li X, Zhu J, et al. The m6A reader YTHDF1 regulates axon guidance through translational control of Robo3.1 expression. Nuc Acids Res. 2019;47:4765–77.

23.

Zhou J, Wan J, Gao X, et al. Dynamic m(6)A mRNA methylation directs translational control of heat shock response. Nature. 2015;526:591–4.PubMedPubMedCentral

24.

Du H, Zhao Y, He J, et al. YTHDF2 destabilizes m(6)A-containing RNA through direct recruitment of the CCR4-NOT deadenylase complex. Nat Commun. 2016;7:12626.PubMedPubMedCentral

25.

Shi H, Wang X, Lu Z, et al. YTHDF3 facilitates translation and decay of N(6)-methyladenosine-modified RNA. Cell Res. 2017;27:315–28.PubMedPubMedCentral

26.

Li A, Chen YS, Ping XL, et al. Cytoplasmic m(6)A reader YTHDF3 promotes mRNA translation. Cell Res. 2017;27:444–7.PubMedPubMedCentral

27.

Roundtree IA, Luo GZ, Zhang Z, et al. YTHDC1 mediates nuclear export of N(6)-methyladenosine methylated mRNAs. Elife. 2017;6.

28.

Mao Y, Dong L, Liu XM, et al. m(6)A in mRNA coding regions promotes translation via the RNA helicase-containing YTHDC2. Nat Commun. 2019;10:5332.PubMedPubMedCentral

29.

Liu N, Dai Q, Zheng G, et al. N(6)-methyladenosine-dependent RNA structural switches regulate RNA-protein interactions. Nature. 2015;518:560–4.PubMedPubMedCentral

30.

Zhou KI, Shi H, Lyu R, et al. Regulation of co-transcriptional pre-mRNA splicing by m(6)A through the low-complexity protein hnRNPG. Mol Cell. 2019;76(70–81): e9.

31.

Alarcon CR, Goodarzi H, Lee H, et al. HNRNPA2B1 is a mediator of m(6)A-dependent nuclear RNA processing events. Cell. 2015;162:1299–308.PubMedPubMedCentral

32.

Meyer KD, Patil DP, Zhou J, et al. 5’ UTR m(6)A promotes cap-independent translation. Cell. 2015;163:999–1010.PubMedPubMedCentral

33.

Huang H, Weng H, Sun W, et al. Recognition of RNA N(6)-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat Cell Biol. 2018;20:285–95.PubMedPubMedCentral

34.

He PC, He C. m(6) A RNA methylation: from mechanisms to therapeutic potential. EMBO J. 2021;40: e105977.PubMedPubMedCentral

35.

Friedman SL. Liver fibrosis—from bench to bedside. J Hepatol. 2003;38(Suppl 1):S38-53.PubMed

36.

Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115:209–18.PubMedPubMedCentral

37.

Cui Z, Huang N, Liu L, et al. Dynamic analysis of m6A methylation spectroscopy during progression and reversal of hepatic fibrosis. Epigenomics. 2020;12:1707–23.PubMed

38.

Fan C, Ma Y, Chen S, et al. Comprehensive analysis of the transcriptome-wide m6A methylation modification difference in liver fibrosis mice by high-throughput m6A sequencing. Front Cell Dev Biol. 2021;9: 767051.PubMedPubMedCentral

39.

Wang Y, Zhao Y, Wang Z, et al. Peroxiredoxin 3 inhibits acetaminophen-induced liver pyroptosis through the regulation of mitochondrial ROS. Front Immunol. 2021;12: 652782.PubMedPubMedCentral

40.

Geng Y, Wang Y, Sun R, et al. Carnosol alleviates nonalcoholic fatty liver disease by inhibiting mitochondrial dysfunction and apoptosis through targeting of PRDX3. Toxicol Appl Pharmacol. 2021;432: 115758.PubMed

41.

Sun R, Tian X, Li Y, et al. The m6A reader YTHDF3-mediated PRDX3 translation alleviates liver fibrosis. Redox Biol. 2022;54: 102378.PubMedPubMedCentral

42.

Yang JJ, Wang J, Yang Y, et al. ALKBH5 ameliorated liver fibrosis and suppressed HSCs activation via triggering PTCH1 activation in an m(6)A dependent manner. Eur J Pharmacol. 2022;922: 174900.PubMed

43.

Shen M, Guo M, Li Y, et al. m(6)A methylation is required for dihydroartemisinin to alleviate liver fibrosis by inducing ferroptosis in hepatic stellate cells. Free Radic Biol Med. 2022;182:246–59.PubMed

44.

Shen M, Li Y, Wang Y, et al. N(6)-methyladenosine modification regulates ferroptosis through autophagy signaling pathway in hepatic stellate cells. Redox Biol. 2021;47: 102151.PubMedPubMedCentral

45.

Zhao T, Qi J, Liu T, et al. N6-methyladenosine modification participates in the progression of hepatitis B virus-related liver fibrosis by regulating immune cell infiltration. Front Med (Lausanne). 2022;9: 821710.PubMed

46.

Shu B, Zhou YX, Li H, et al. The METTL3/MALAT1/PTBP1/USP8/TAK1 axis promotes pyroptosis and M1 polarization of macrophages and contributes to liver fibrosis. Cell Death Discov. 2021;7:368.PubMedPubMedCentral

47.

Luo Y, Zhang Z, Xiang L, et al. Analysis of N6-methyladenosine methylation modification in fructose-induced non-alcoholic fatty liver disease. Front Endocrinol (Lausanne). 2021;12: 780617.PubMed

48.

Zhong X, Yu J, Frazier K, et al. Circadian clock regulation of hepatic lipid metabolism by modulation of m(6)A mRNA methylation. Cell Rep. 2018;25(1816–28): e4.

49.

Feng Y, Dong H, Sun B, et al. METTL3/METTL14 Transactivation and m(6)A-dependent TGF-beta1 translation in activated kupffer cells. Cell Mol Gastroenterol Hepatol. 2021;12:839–56.PubMedPubMedCentral

50.

Kang H, Zhang Z, Yu L, et al. FTO reduces mitochondria and promotes hepatic fat accumulation through RNA demethylation. J Cell Biochem. 2018;119:5676–85.PubMed

51.

Guo J, Ren W, Li A, et al. Fat mass and obesity-associated gene enhances oxidative stress and lipogenesis in nonalcoholic fatty liver disease. Dig Dis Sci. 2013;58:1004–9.PubMed

52.

Hu Y, Feng Y, Zhang L, et al. GR-mediated FTO transactivation induces lipid accumulation in hepatocytes via demethylation of m(6)A on lipogenic mRNAs. RNA Biol. 2020;17:930–42.PubMedPubMedCentral

53.

Li Y, Zhang Q, Cui G, et al. m(6)A regulates liver metabolic disorders and hepatogenous diabetes. Genom Proteom Bioinform. 2020;18:371–83.

54.

Qin Y, Li B, Arumugam S, et al. m(6)A mRNA methylation-directed myeloid cell activation controls progression of NAFLD and obesity. Cell Rep. 2021;37: 109968.PubMedPubMedCentral

55.

Zhou B, Liu C, Xu L, et al. N(6)-methyladenosine reader protein YT521-B homology domain-containing 2 suppresses liver steatosis by regulation of mRNA stability of lipogenic genes. Hepatology. 2021;73:91–103.PubMed

56.

Peneau C, Imbeaud S, La Bella T, et al. Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma. Gut. 2022;71:616–26.PubMed

57.

Li TY, Yang Y, Zhou G, et al. Immune suppression in chronic hepatitis B infection associated liver disease: a review. World J Gastroenterol. 2019;25:3527–37.PubMedPubMedCentral

58.

Kim GW, Siddiqui A. Hepatitis B virus X protein recruits methyltransferases to affect cotranscriptional N6-methyladenosine modification of viral/host RNAs. Proc Natl Acad Sci USA. 2021;118.

59.

Kim GW, Imam H, Siddiqui A. The RNA binding proteins YTHDC1 and FMRP regulate the nuclear export of N(6)-methyladenosine-modified hepatitis B virus transcripts and affect the viral life cycle. J Virol. 2021;95: e0009721.PubMed

60.

Imam H, Khan M, Gokhale NS, et al. N6-methyladenosine modification of hepatitis B virus RNA differentially regulates the viral life cycle. Proc Natl Acad Sci USA. 2018;115:8829–34.PubMedPubMedCentral

61.

Kim GW, Moon JS, Siddiqui A. N6-methyladenosine modification of the 5' epsilon structure of the HBV pregenome RNA regulates its encapsidation by the viral core protein. Proc Natl Acad Sci USA. 2022;119.

62.

Kim GW, Siddiqui A. Hepatitis B virus X protein expression is tightly regulated by N6-methyladenosine modification of its mRNA. J Virol. 2022;96: e0165521.PubMed

63.

Kim GW, Imam H, Khan M, et al. HBV-induced increased N6 methyladenosine modification of PTEN RNA affects innate immunity and contributes to HCC. Hepatology. 2021;73:533–47.PubMed

64.

Kim GW, Imam H, Khan M, et al. N(6)-methyladenosine modification of hepatitis B and C viral RNAs attenuates host innate immunity via RIG-I signaling. J Biol Chem. 2020;295:13123–33.PubMedPubMedCentral

65.

Imam H, Kim GW, Mir SA, et al. Interferon-stimulated gene 20 (ISG20) selectively degrades N6-methyladenosine modified Hepatitis B Virus transcripts. PLoS Pathog. 2020;16: e1008338.PubMedPubMedCentral

66.

Qu S, Jin L, Huang H, et al. A positive-feedback loop between HBx and ALKBH5 promotes hepatocellular carcinogenesis. BMC Cancer. 2021;21:686.PubMedPubMedCentral

67.

Tao L, Li D, Mu S, et al. LncRNA MAPKAPK5_AS1 facilitates cell proliferation in hepatitis B virus -related hepatocellular carcinoma. Lab Invest. 2022;102:494–504.PubMed

68.

Rao X, Lai L, Li X, et al. N(6)-methyladenosine modification of circular RNA circ-ARL3 facilitates Hepatitis B virus-associated hepatocellular carcinoma via sponging miR-1305. IUBMB Life. 2021;73:408–17.PubMed

69.

Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.PubMed

70.

Chen M, Wei L, Law CT, et al. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2. Hepatology. 2018;67:2254–70.PubMed

71.

Lin X, Chai G, Wu Y, et al. RNA m(6)A methylation regulates the epithelial mesenchymal transition of cancer cells and translation of Snail. Nat Commun. 2019;10:2065.PubMedPubMedCentral

72.

Qiao K, Liu Y, Xu Z, et al. RNA m6A methylation promotes the formation of vasculogenic mimicry in hepatocellular carcinoma via Hippo pathway. Angiogenesis. 2021;24:83–96.PubMed

73.

Xu H, Wang H, Zhao W, et al. SUMO1 modification of methyltransferase-like 3 promotes tumor progression via regulating Snail mRNA homeostasis in hepatocellular carcinoma. Theranostics. 2020;10:5671–86.PubMedPubMedCentral

74.

Chen Y, Peng C, Chen J, et al. WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1. Mol Cancer. 2019;18:127.PubMedPubMedCentral

75.

Chou J, Lin JH, Brenot A, et al. GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression. Nat Cell Biol. 2013;15:201–13.PubMedPubMedCentral

76.

Lan T, Li H, Zhang D, et al. KIAA1429 contributes to liver cancer progression through N6-methyladenosine-dependent post-transcriptional modification of GATA3. Mol Cancer. 2019;18:186.PubMedPubMedCentral

77.

Liu X, Liu J, Xiao W, et al. SIRT1 Regulates N(6)-methyladenosine RNA modification in hepatocarcinogenesis by inducing RANBP2-dependent FTO SUMOylation. Hepatology. 2020;72:2029–50.PubMed

78.

Chen Y, Zhao Y, Chen J, et al. ALKBH5 suppresses malignancy of hepatocellular carcinoma via m(6)A-guided epigenetic inhibition of LYPD1. Mol Cancer. 2020;19:123.PubMedPubMedCentral

79.

Zhang C, Huang S, Zhuang H, et al. YTHDF2 promotes the liver cancer stem cell phenotype and cancer metastasis by regulating OCT4 expression via m6A RNA methylation. Oncogene. 2020;39:4507–18.PubMed

80.

Zhong L, Liao D, Zhang M, et al. YTHDF2 suppresses cell proliferation and growth via destabilizing the EGFR mRNA in hepatocellular carcinoma. Cancer Lett. 2019;442:252–61.PubMed

81.

Ma Y, Han CC, Li Y, et al. Insulin-like growth factor-binding protein-3 inhibits IGF-1-induced proliferation of human hepatocellular carcinoma cells by controlling bFGF and PDGF autocrine/paracrine loops. Biochem Biophys Res Commun. 2016;478:964–9.PubMed

82.

Nguyen LH, Robinton DA, Seligson MT, et al. Lin28b is sufficient to drive liver cancer and necessary for its maintenance in murine models. Cancer Cell. 2014;26:248–61.PubMedPubMedCentral

83.

Ma JZ, Yang F, Zhou CC, et al. METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N(6)-methyladenosine-dependent primary MicroRNA processing. Hepatology. 2017;65:529–43.PubMed

84.

Zuo X, Chen Z, Gao W, et al. M6A-mediated upregulation of LINC00958 increases lipogenesis and acts as a nanotherapeutic target in hepatocellular carcinoma. J Hematol Oncol. 2020;13:5.PubMedPubMedCentral

85.

Xia A, Yuan W, Wang Q, et al. The cancer-testis lncRNA lnc-CTHCC promotes hepatocellular carcinogenesis by binding hnRNP K and activating YAP1 transcription. Nat Cancer. 2022;3:203–18.PubMed

86.

Chen YT, Xiang D, Zhao XY, et al. Upregulation of lncRNA NIFK-AS1 in hepatocellular carcinoma by m(6)A methylation promotes disease progression and sorafenib resistance. Hum Cell. 2021;34:1800–11.PubMed

87.

Peng L, Pan B, Zhang X, et al. Lipopolysaccharide facilitates immune escape of hepatocellular carcinoma cells via m6A modification of lncRNA MIR155HG to upregulate PD-L1 expression. Cell Biol Toxicol. 2022.

88.

Liang W, Wang Y, Zhang Q, et al. M(6)A-mediated upregulation of LINC00106 promotes stemness and metastasis properties of hepatocellular carcinoma via sponging Let7f. Front Cell Dev Biol. 2021;9: 781867.PubMedPubMedCentral

89.

Dai YZ, Liu YD, Li J, et al. METTL16 promotes hepatocellular carcinoma progression through downregulating RAB11B-AS1 in an m(6)A-dependent manner. Cell Mol Biol Lett. 2022;27:41.PubMedPubMedCentral

90.

Rong D, Wu F, Lu C, et al. m6A modification of circHPS5 and hepatocellular carcinoma progression through HMGA2 expression. Mol Ther Nucl Acids. 2021;26:637–48.

91.

Du A, Li S, Zhou Y, et al. M6A-mediated upregulation of circMDK promotes tumorigenesis and acts as a nanotherapeutic target in hepatocellular carcinoma. Mol Cancer. 2022;21:109.PubMedPubMedCentral

92.

Liu H, Lan T, Li H, et al. Circular RNA circDLC1 inhibits MMP1-mediated liver cancer progression via interaction with HuR. Theranostics. 2021;11:1396–411.PubMedPubMedCentral

93.

Chen Y, Ling Z, Cai X, et al. Activation of YAP1 by N6-methyladenosine-modified circCPSF6 drives malignancy in hepatocellular carcinoma. Cancer Res. 2022;82:599–614.PubMed

94.

Duan JL, Chen W, Xie JJ, et al. A novel peptide encoded by N6-methyladenosine modified circMAP3K4 prevents apoptosis in hepatocellular carcinoma. Mol Cancer. 2022;21:93.PubMedPubMedCentral

95.

Wu A, Hu Y, Xu Y, et al. Methyltransferase-like 3-mediated m6A methylation of Hsa_circ_0058493 accelerates hepatocellular carcinoma progression by binding to YTH domain-containing protein 1. Front Cell Dev Biol. 2021;9: 762588.PubMedPubMedCentral

96.

Liu L, Gu M, Ma J, et al. CircGPR137B/miR-4739/FTO feedback loop suppresses tumorigenesis and metastasis of hepatocellular carcinoma. Mol Cancer. 2022;21:149.PubMedPubMedCentral

97.

Qu N, Bo X, Li B, et al. Role of N6-methyladenosine (m(6)A) methylation regulators in hepatocellular carcinoma. Front Oncol. 2021;11: 755206.PubMedPubMedCentral

98.

Bo C, Li N, He L, et al. Long non-coding RNA ILF3-AS1 facilitates hepatocellular carcinoma progression by stabilizing ILF3 mRNA in an m(6)A-dependent manner. Hum Cell. 2021;34:1843–54.PubMed

99.

Chen F, Li M, Wang L. LncRNA CASC11 promotes hepatocellular carcinoma progression via upregulation of UBE2T in a m(6)A-dependent manner. Front Oncol. 2021;11: 772671.PubMedPubMedCentral

100.

Chen J, Zhou X, Wu W, et al. FTO-dependent function of N6-methyladenosine is involved in the hepatoprotective effects of betaine on adolescent mice. J Physiol Biochem. 2015;71:405–13.PubMed

101.

Dang Y, Hao S, Zhou W, et al. The traditional Chinese formulae Ling-gui-zhu-gan decoction alleviated non-alcoholic fatty liver disease via inhibiting PPP1R3C mediated molecules. BMC Complement Altern Med. 2019;19:8.PubMedPubMedCentral

102.

Liu T, Yang LL, Zou L, et al. Chinese medicine formula lingguizhugan decoction improves beta-oxidation and metabolism of fatty acid in high-fat-diet-induced rat model of fatty liver disease. Evid Based Complement Alternat Med. 2013;2013: 429738.PubMedPubMedCentral

103.

Dang Y, Xu J, Yang Y, et al. Ling-gui-zhu-gan decoction alleviates hepatic steatosis through SOCS2 modification by N6-methyladenosine. Biomed Pharmacother. 2020;127: 109976.PubMed

104.

Chen YW, Liu BW, Zhang YJ, et al. Preservation of basal AcSDKP attenuates carbon tetrachloride-induced fibrosis in the rat liver. J Hepatol. 2010;53:528–36.PubMed

105.

Wei A, Zhao F, Hao A, et al. N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) mitigates the liver fibrosis via WTAP/m(6)A/Ptch1 axis through Hedgehog pathway. Gene. 2022;813: 146125.PubMed

106.

Lu N, Li X, Yu J, et al. Curcumin attenuates lipopolysaccharide-induced hepatic lipid metabolism disorder by modification of m(6) A RNA methylation in piglets. Lipids. 2018;53:53–63.PubMed

107.

Peng S, Xiao W, Ju D, et al. Identification of entacapone as a chemical inhibitor of FTO mediating metabolic regulation through FOXO1. Sci Transl Med. 2019;11.

108.

Chen B, Ye F, Yu L, et al. Development of cell-active N6-methyladenosine RNA demethylase FTO inhibitor. J Am Chem Soc. 2012;134:17963–71.PubMed

109.

Li Q, Huang Y, Liu X, et al. Rhein inhibits AlkB repair enzymes and sensitizes cells to methylated DNA damage. J Biol Chem. 2016;291:11083–93.PubMedPubMedCentral

110.

Su R, Dong L, Li C, et al. R-2HG exhibits anti-tumor activity by targeting FTO/m(6)A/MYC/CEBPA signaling. Cell. 2018;172(90–105): e23.

111.

Huang Y, Su R, Sheng Y, et al. Small-molecule targeting of oncogenic FTO demethylase in acute myeloid leukemia. Cancer Cell. 2019;35(677–91): e10.

Title: N6-methyladenosine RNA methylation in liver diseases: from mechanism to treatment
Authors: Lan Yang
Siyuan Tian
Xiaohong Zheng
Miao Zhang
Xinmin Zhou
Yulong Shang
Ying Han
Publication date: 28-06-2023
Publisher: Springer Nature Singapore
Keywords: Hepatocellular Carcinoma
Hepatocellular Carcinoma
Hepatitis B
Published in: Journal of Gastroenterology / Issue 8/2023
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI: https://doi.org/10.1007/s00535-023-02008-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2023

Real-world efficacy of antibiotic prophylaxis for upper gastrointestinal bleeding in cirrhotic patients in Japan

Standard versus delayed initiation of S-1 adjuvant chemotherapy after surgery for pancreatic cancer: a secondary analysis of a nationwide cohort by the Japan Pancreas Society

Proton pump inhibitor use and risk of pneumonia: a self-controlled case series study

Association of ulcerative colitis symptom severity and proctocolectomy with multidimensional patient-reported outcomes: a cross-sectional study

Sessile serrated lesions with dysplasia: is it possible to nip them in the bud?

Computer-aided demarcation of early gastric cancer: a pilot comparative study with endoscopists

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials